|
1
|
Gilliam FG, Black KJ, Carter J, Freedland
KE, Sheline YI, Tsai WY and Lustman PJ: A trial of sertraline or
cognitive behavior therapy for depression in epilepsy. Ann Neurol.
86:552–560. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Englot DJ, Rolston JD, Wright CW, Hassnain
KH and Chang EF: Rates and predictors of seizure freedom with vagus
nerve stimulation for intractable epilepsy. Neurosurgery.
79:345–353. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kanner AM, Ashman E, Gloss D, Harden C,
Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E,
Llanas Park E, Stern J, et al: Practice guideline update summary:
Efficacy and tolerability of the new antiepileptic drugs II:
Treatment-resistant epilepsy: Report of the guideline development,
dissemination, and implementation subcommittee of the American
academy of neurology and the American epilepsy society. Neurology.
91:82–90. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chen Z, Brodie MJ, Liew D and Kwan P:
Treatment outcomes in patients with newly diagnosed epilepsy
treated with established and new antiepileptic drugs: A 30-year
longitudinal cohort study. JAMA Neurol. 75:279–286. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bouwens van der Vlis TAM, Schijns OEMG,
Schaper FLWVJ, Hoogland G, Kubben P, Wagner L, Rouhl R, Temel Y and
Ackermans L: Deep brain stimulation of the anterior nucleus of the
thalamus for drug-resistant epilepsy. Neurosurg Rev. 42:287–296.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Grinspan ZM, Shellhaas RA, Coryell J,
Sullivan JE, Wirrell EC, Mytinger JR, Gaillard WD, Kossoff EH,
Valencia I, Knupp KG, et al: Comparative effectiveness of
levetiracetam vs phenobarbital for infantile epilepsy. JAMA
Pediatr. 172:352–360. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shiek Ahmad B, O'Brien TJ, Gorelik A, Hill
KD and Wark JD: Bone mineral changes in epilepsy patients during
initial years of antiepileptic drug therapy. J Clin Densitom.
19:450–456. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Phabphal K, Geater A, Limapichart K,
Sathirapanya P, Setthawatcharawanich S, Witeerungrot N,
Thammakumpee N and Leelawattana R: The association between BsmI
polymorphism and bone mineral density in young patients with
epilepsy who are taking phenytoin. Epilepsia. 54:249–255.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gupta M: Levetiracetam-induced
leukocytoclastic vasculitis. Indian J Pharmacol. 49:124–126.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Arican P, Gencpinar P, Cavusoglu D and
Olgac Dundar N: Levetiracetam monotherapy for the treatment of
infants with epilepsy. Seizure. 56:73–77. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kellinghaus C: Lacosamide as treatment for
partial epilepsy: Mechanisms of action, pharmacology, effects, and
safety. Ther Clin Risk Manag. 5:757–766. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Niespodziany I, Leclère N, Vandenplas C,
Foerch P and Wolff C: Comparative study of lacosamide and classical
sodium channel blocking antiepileptic drugs on sodium channel slow
inactivation. J Neurosci Res. 91:436–443. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wilson SM and Khanna R: Specific binding
of lacosamide to collapsin response mediator protein 2 (CRMP2) and
direct impairment of its canonical function: Implications for the
therapeutic potential of lacosamide. Mol Neurobiol. 51:599–609.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Saadi A, Patenaude B and Mateen FJ:
Quality of life in epilepsy-31 inventory (QOLIE-31) scores: A
global comparison. Epilepsy Behav. 65:13–17. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Linane A, Lagrange AH, Fu C and
Abou-Khalil B: Generalized onset seizures with focal evolution
(GOFE)-A unique seizure type in the setting of generalized
epilepsy. Epilepsy Behav. 54:20–29. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xue-Ping W, Hai-Jiao W, Li-Na Z, Xu D and
Ling L: Risk factors for drug-resistant epilepsy: A systematic
review and meta-analysis. Medicine (Baltimore).
98(e16402)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Weisman H, Fried I, Gilboa T, Bennett-Back
O, Ekstein D, Shweiki M, Shoshan Y and Benifla M: Prevalence,
characteristics, and long-term prognosis of epilepsy associated
with pediatric brain tumors. World Neurosurg. 109:e594–e600.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ruffolo G, Di Bonaventura C, Cifelli P,
Roseti C, Fattouch J, Morano A, Limatola C, Aronica E, Palma E and
Giallonardo AT: A novel action of lacosamide on GABAA currents sets
the ground for a synergic interaction with levetiracetam in
treatment of epilepsy. Neurobiol Dis. 115:59–68. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gulati P, Cannell P, Ghia T, Bint L, Walsh
P, Ghosh S and Nagarajan L: Lacosamide as adjunctive therapy in
treatment-resistant epilepsy in childhood. J Paediatr Child Health.
51:794–797. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kaciński M, Budziszewska B, Lasoń W, Zajac
A, Skowronek-Bała B, Leśkiewicz M, Kubik A and Basta-Kaim A: Level
of S100B protein, neuron specific enolase, orexin A, adiponectin
and insulin-like growth factor in serum of pediatric patients
suffering from sleep disorders with or without epilepsy. Pharmacol
Rep. 64:1427–1433. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang LG, Zhai QX, Tang ZH, Zhang YX, Guo
YX, Chen ZH, Wang C, Zhuo MQ, Zeng XL and Zhang JW: Effect of
ilepcimide combined western drugs on serum level of neuron specific
enolase in treating epilepsy children patients. Zhongguo Zhong Xi
Yi Jie He Za Zhi. 36:912–915. 2016.PubMed/NCBI(In Chinese).
|
|
22
|
Xu Z, Xue T, Zhang Z, Wang X, Xu P, Zhang
J, Lei X, Li Y, Xie Y, Wang L, et al: Role of signal transducer and
activator of transcription-3 in up-regulation of GFAP after
epilepsy. Neurochem Res. 36:2208–2215. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chang CC, Lui CC, Lee CC, Chen SD, Chang
WN, Lu CH, Chen NC, Chang AY, Chan SH and Chuang YC: Clinical
significance of serological biomarkers and neuropsychological
performances in patients with temporal lobe epilepsy. BMC Neurol.
12(15)2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fu J, Peng L, Li J, Tao T and Chen Y:
Effects of second-generation antiepileptic drugs compared to
first-generation antiepileptic drugs on bone metabolism in patients
with epilepsy: A meta-analysis. Horm Metab Res. 51:511–521.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mintzer S, Boppana P, Toguri J and
DeSantis A: Vitamin D levels and bone turnover in epilepsy patients
taking carbamazepine or oxcarbazepine. Epilepsia. 47:510–515.
2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fernandez H, Cooke M and Patel T: Epilepsy
and lifestyle behaviors related to bone health. Epilepsia.
60:2306–2313. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Beniczky SA, Viken J, Jensen LT and
Andersen NB: Bone mineral density in adult patients treated with
various antiepileptic drugs. Seizure. 21:471–472. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Anwar MJ, Radhakrishna KV and Vohora D:
Phenytoin and sodium valproate but not levetiracetam induce bone
alterations in female mice. Can J Physiol Pharmacol. 92:507–511.
2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
El-Haggar SM, Mostafa TM, Allah HMS and
Akef GH: Levetiracetam and lamotrigine effects as mono- and
polytherapy on bone mineral density in epileptic patients. Arq
Neuropsiquiatr. 76:452–458. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Robins A, Patel M and Azim A: A case of
physical and mental adverse drug reactions associated with
levetiracetam in post-stroke epilepsy. J Am Geriatr Soc.
60:159–160. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen J, Liu XM, Yue X and Chen SZ: The
clinical efficacy and safety of levetiracetam add-on therapy for
child refractory epilepsy. Eur Rev Med Pharmacol Sci. 20:2689–2694.
2016.PubMed/NCBI
|
|
32
|
Rocamora R, Ley M, Molins A, Toledo M,
Sansa G, Bertol V, Becerra JL, Carreño M and Mauri JÁ: Effect of
lacosamide on depression and anxiety symptoms in patients with
focal refractory epilepsy: A prospective multicenter study.
Epilepsy Behav. 79:87–92. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nakhutina L, Kunnakkat SD, Coleman M,
Lushbough C, Arnedo V, Soni N and Grant AC: Effects of adjunctive
lacosamide on mood and quality of life in patients with epilepsy.
Epilepsy Behav. 73:90–94. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Böttcher S, Lutz MT and Mayer T:
Lacosamide in the treatment of patients with epilepsy and
intellectual disabilities: A long-term study of 136 patients.
Epilepsia. 58:1749–1754. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sunwoo JS, Park BS, Ahn SJ, Hwang S, Park
CY, Jun JS, Kim DW, Lee ST, Jung KH, Park KI, et al: Three-year
retention rates of levetiracetam, topiramate, and oxcarbazepine: A
retrospective hospital-based study. Clin Neuropharmacol. 40:56–62.
2017.PubMed/NCBI View Article : Google Scholar
|
